{"id":13674,"date":"2016-01-07T14:25:51","date_gmt":"2016-01-07T14:25:51","guid":{"rendered":"http:\/\/www.asperbio.com\/?page_id=13674"},"modified":"2017-12-06T10:48:38","modified_gmt":"2017-12-06T08:48:38","slug":"mitteinvasiivne-sunnieelne-testimine","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-reprogenetics-testid-2\/mitteinvasiivne-sunnieelne-testimine\/","title":{"rendered":"Mitteinvasiivne s\u00fcnnieelne testimine"},"content":{"rendered":"<h2 style=\"padding-left: 5px;\"><span style=\"color: #e63458;\">Mitteinvasiivne s\u00fcnnieelne testimine<\/span><\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/t-roosa.png') repeat-y; padding-left: 40px;\">\n<p style=\"text-align: justify;\">Lisaks invasiivsetele s\u00fcnnieelsetele protseduuridele nagu amniotsentees ja koorionihattude biopsia on loote\u00a0kromosoomimuutusi v\u00f5imalik n\u00fc\u00fcd m\u00e4\u00e4rata ka <strong>ema vereproovist<\/strong> loote rakuvaba DNA anal\u00fc\u00fcsimise kaudu. Testida saab juba alates\u00a0<strong>10. rasedusn\u00e4dalast<\/strong>\u00a0ja sellega ei kaasne riski raseduse katkemiseks.<\/p>\n<p style=\"text-align: justify;\">Sequenom Laboratories on v\u00e4lja t\u00f6\u00f6tanud kaks mitteinvasiivset s\u00fcnnieelset testi &#8211; <strong>MaterniT21\u2122 PLUS<\/strong> ja <strong>VisibiliT\u2122<\/strong>. Testide tulemused saab juba <strong>viie p\u00e4eva<\/strong> jooksul p\u00e4rast proovide laborisse j\u00f5udmist. \u00a0Vastused sisaldavad p\u00f5hjalikku informatsiooni loote kromosoomistiku kohta.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-20961 alignright\" src=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/MaterniT21-PLUS-s\u00fcnnieelne-test-200x300.jpg\" alt=\"MaterniT21-PLUS-loote-test-ema-verest\" width=\"200\" height=\"300\" srcset=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/MaterniT21-PLUS-s\u00fcnnieelne-test-200x300.jpg 200w, https:\/\/www.asperbio.com\/wp-content\/uploads\/MaterniT21-PLUS-s\u00fcnnieelne-test-768x1152.jpg 768w, https:\/\/www.asperbio.com\/wp-content\/uploads\/MaterniT21-PLUS-s\u00fcnnieelne-test-683x1024.jpg 683w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n<h2 style=\"text-align: justify;\"><span style=\"color: #e63458;\">MaterniT21\u2122 PLUS test<\/span><\/h2>\n<p style=\"text-align: justify;\">MaterniT21\u2122 PLUS mitteinvasiivne test annab p\u00f5hjalikku teavet sagedasemate <strong>kromosoomimuutuste<\/strong> ja <strong>mikrodeletsioonide<\/strong> kohta. Soovi korral m\u00e4\u00e4ratakse ka loote sugu.<\/p>\n<p style=\"text-align: justify;\">MaterniT21\u2122 PLUS testiga on v\u00f5imalik m\u00e4\u00e4rata j\u00e4rgmisi <strong>s\u00fcndroome<\/strong>:<\/p>\n<p style=\"text-align: justify;\">Downi s\u00fcndroom (trisoomia 21),\u00a0Edwardsi s\u00fcndroom (trisoomia 18),\u00a0Patau s\u00fcndroom (trisoomia 13),\u00a0Trisoomia 16,\u00a0Trisoomia 22,\u00a0Turneri s\u00fcndroom (45, X),\u00a0Klinefelteri s\u00fcndroom 47, XXY,\u00a0Triple X s\u00fcndroom (47, XXX),\u00a0XYY s\u00fcndroom (47, XYY),\u00a0DiGeorge&#8217;i s\u00fcndroom (22q),\u00a0Cri-du-chat s\u00fcndroom (5p), 1p36 deletsiooni\u00a0s\u00fcndroom,\u00a0Angelmani s\u00fcndroom (15q),\u00a0Prader-Willi s\u00fcndroom (15q),\u00a0Jacobseni s\u00fcndroom (11q),\u00a0Langer-Giedioni s\u00fcndroom (8q),\u00a0Wolf-Hirschhorni s\u00fcndroom (4p).<\/p>\n<p><strong>Test on<\/strong> <strong>n\u00e4idustatud rasedatele<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li>kes kuuluvad riskigruppi (35-aastased ja vanemad, leid s\u00fcnnieelses s\u00f5eluuringus v\u00f5i ultrahelis, eelnev perekondlik anamnees)<\/li>\n<li>kellel on \u00fcksik- v\u00f5i mitmikrasedus<\/li>\n<li>kes soovivad detailsemat geneetilist informatsiooni haruldaste kromosoomih\u00e4irete kohta<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">MaterniT21\u2122 PLUS testi eelised:<\/p>\n<ul style=\"text-align: justify;\">\n<li>V\u00f5imaldab anal\u00fc\u00fcsida rohkem kromosoomipiirkondi kui \u00fckski teine mitteinvasiivne s\u00fcnnieelne test<\/li>\n<li>T\u00e4pne ja p\u00f5hjalik info kromosoomimuutuste kohta (sealhulgas mikrodeletsioonid)<\/li>\n<li>Selged ja lihtsad vastused<\/li>\n<li>V\u00e4ga madal vastuseta j\u00e4\u00e4nud proovide hulk (&lt;1,5%), seega minimaalne kordusproovi v\u00f5tmise vajadus<\/li>\n<\/ul>\n<h2 style=\"text-align: justify;\"><span style=\"color: #e63458;\">Visib<span style=\"color: #e63458;\">iliT<\/span>\u2122 test<\/span><\/h2>\n<p>VisibiliT\u2122 mitteinvasiivse testi abil m\u00e4\u00e4ratakse kahte sagedasemat loote kromosoomimuutust \u2013 <strong>Downi s\u00fcndroomi<\/strong> ja <strong>Edwardsi s\u00fcndroomi<\/strong>. Soovi korral tehakse kindlaks ka loote sugu.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Test on<\/strong> <strong>n\u00e4idustatud rasedatele<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li>kes soovivad t\u00e4pset Downi s\u00fcndroomi (trisoomia21) ja Edwardsi s\u00fcndroomi (trisoomia 18) anal\u00fc\u00fcsi<\/li>\n<li>kellel on \u00fcksikrasedus<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">VisibiliT\u2122 testi eelised:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Downi s\u00fcndroomi ja Edwardsi s\u00fcndroomi m\u00e4\u00e4ramise t\u00e4psus on \u00fcle 99%<\/li>\n<li>Trisoomiate kohta saadav teave sarnaneb s\u00f5eltestidest saadava infoga<\/li>\n<li>V\u00e4ga madal vale-positiivsete leidude hulk v\u00f5rreldes s\u00f5eltestidega<\/li>\n<li>V\u00e4ga madal vastuseta j\u00e4\u00e4nud proovide hulk (&lt;1,5%), seega minimaalne kordusproovi v\u00f5tmise vajadus<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<h3><span style=\"color: #e63458;\"><a style=\"color: #e63458;\" title=\"MaterniT21 PLUS ja VisibiliT testide tellimisinfo\" href=\"https:\/\/www.asperbio.com\/et\/asper-reprogenetics-testid-2\/mitteinvasiivne-sunnieelne-testimine\/maternit21-plus-ja-visibilit-sunnieelsete-testide-tellimine\">&gt; MaterniT21 PLUS ja VisibiliT testide tellimisinfo<\/a><\/span><\/h3>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<p>&nbsp;<\/p>\n<h4 style=\"text-align: justify;\"><\/h4>\n<p style=\"text-align: justify;\">Viited:<\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 8pt;\">Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin; Number 77, January 2007.<\/span><br \/>\n<span style=\"font-size: 8pt;\"> Kim S, et al. Application of risk-score analysis to low-coverage sequencing data for noninvasive detection of trisomy 21 and trisomy 18. Poster presented at the 18th International Conference on Prenatal Diagnosis and Therapy; July 2014; Brisbane, Australia.<\/span><br \/>\n<span style=\"font-size: 8pt;\"> Palomaki GE, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13, as well as Down syndrome: An international collaborative study. Genet Med. 2012;14(3):296-305.<\/span><br \/>\n<span style=\"font-size: 8pt;\"> Mazloom AR, Dzakula Z, Oeth P, Wang H, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. <i>Prenat Diagn<\/i>. 2013;33(6):591-597.<\/span><br \/>\n<span style=\"font-size: 8pt;\"> Canick JA, et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. <i>Prenat Diagn<\/i>. 2012;32(8):730-734.<\/span><br \/>\n<span style=\"font-size: 8pt;\"> Zhao C, et al. Detection of fetal subchromosomal abnormalities by sequencing\u00a0 CCF from maternal plasma. Poster presented at the ACMG Annual Clinical Genetics Meeting; March 2014; Nashville, TN.<\/span><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Mitteinvasiivne s\u00fcnnieelne testimine Lisaks invasiivsetele s\u00fcnnieelsetele protseduuridele nagu amniotsentees ja koorionihattude biopsia on loote\u00a0kromosoomimuutusi v\u00f5imalik n\u00fc\u00fcd m\u00e4\u00e4rata ka ema vereproovist loote rakuvaba DNA anal\u00fc\u00fcsimise kaudu. Testida saab juba alates\u00a010. rasedusn\u00e4dalast\u00a0ja sellega ei kaasne riski raseduse katkemiseks. Sequenom Laboratories on v\u00e4lja t\u00f6\u00f6tanud kaks mitteinvasiivset s\u00fcnnieelset testi &#8211; MaterniT21\u2122 PLUS ja VisibiliT\u2122. Testide tulemused saab juba viie [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":11436,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-13674","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/13674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=13674"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/13674\/revisions"}],"predecessor-version":[{"id":20967,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/13674\/revisions\/20967"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/11436"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=13674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}